Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction | Zendy

Kenneth B. Margulies | Zendy; Adrian F. Hernandez | Zendy; Margaret M. Redfield | Zendy; Michael M. Givertz | Zendy; Guilherme H. Oliveira | Zendy; Robert T. Cole | Zendy; Douglas L. Mann | Zendy; David J. Whellan | Zendy; Michael S. Kiernan | Zendy; G. Michael Felker | Zendy; Steven E. McNulty | Zendy; Kevin J. Anstrom | Zendy; Monica Shah | Zendy; Eugene Braunwald | Zendy; Thomas P. Cappola | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction

Author(s) -

Kenneth B. Margulies,

Adrian F. Hernandez,

Margaret M. Redfield,

Michael M. Givertz,

Guilherme H. Oliveira,

Robert T. Cole,

Douglas L. Mann,

David J. Whellan,

Michael S. Kiernan,

G. Michael Felker,

Steven E. McNulty,

Kevin J. Anstrom,

Monica Shah,

Eugene Braunwald,

Thomas P. Cappola

Publication year - 2016

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/jama.2016.10260

Subject(s) - medicine , heart failure , ejection fraction , interquartile range , clinical endpoint , liraglutide , cardiology , natriuretic peptide , placebo , type 2 diabetes , clinical trial , diabetes mellitus , endocrinology , alternative medicine , pathology

Abnormal cardiac metabolism contributes to the pathophysiology of advanced heart failure with reduced left ventricular ejection fraction (LVEF). Glucagon-like peptide 1 (GLP-1) agonists have shown cardioprotective effects in early clinical studies of patients with advanced heart failure, irrespective of type 2 diabetes status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research